Oligomerization and toxicity of Aβ fusion proteins

Biochemical and Biophysical Research Communications

Volumn 409, Issue 3, 2011, Pages 477-482

  Caine, Joanne M ^a   Bharadwaj, Prashant R ^a,b   Sankovich, Sonia E ^a   Ciccotosto, Giuseppe D ^c   Streltsov, Victor A ^a   Varghese, Jose ^a  

^a CSIRO   (Australia)

^b EDITH COWAN UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Alzheimer's disease; Amyloid beta peptide; MBP fusion; Toxicity

Indexed keywords

AMYLOID BETA PROTEIN; HYBRID PROTEIN; MALTOSE BINDING PROTEIN; MALTOSE BINDING PROTEIN AMYLOID BETA 42 FUSION PROTEIN; OLIGOMER; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BRAIN CELL; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG SCREENING; NERVE CELL CULTURE; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; YEAST CELL;

AMYLOID BETA-PEPTIDES; ANIMALS; APOPTOSIS; CEREBRAL CORTEX; MALTOSE-BINDING PROTEINS; MICE; NEURONS; PEPTIDE FRAGMENTS; PROTEIN MULTIMERIZATION; RECOMBINANT FUSION PROTEINS; SACCHAROMYCES CEREVISIAE; SOLUBILITY;

EID: 79958220270     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.05.029     Document Type: Article

References (30)

1. Selkoe D.J. Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. Nat. Cell Biol. 2004, 6:1054-1061.
2. Tiraboschi P., Hansen L.A., Thal L.J., Corey-Bloom J. The importance of neuritic plaques and tangles to the development and evolution of AD. Neurology 2004, 62:1984-1989.
3. Westerman M.A., Cooper-Blacketer D., Mariash A., Kotilinek L., Kawarabayashi T., Younkin L.H., Carlson G.A., Younkin S.G., Ashe K.H. The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J. Neurosci. 2002, 22:1858-1867.
4. Lacor P.N., Buniel M.C., Chang L., Fernandez S.J., Gong Y., Viola K.L., Lambert M.P., Velasco P.T., Bigio E.H., Finch C.E., Krafft G.A., Klein W.L. Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J. Neurosci. 2004, 24:10191-10200.
5. Lue L.F., Kuo Y.M., Roher A.E., Brachova L., Shen Y., Sue L., Beach T., Kurth J.H., Rydel R.E., Rogers J. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol. 1999, 155:853-862.
6. Gong Y., Chang L., Viola K.L., Lacor P.N., Lambert M.P., Finch C.E., Krafft G.A., Klein W.L. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl. Acad. Sci. USA 2003, 100:10417-104122.
7. Cleary J.P., Walsh D.M., Hofmeister J.J., Shankar G.M., Kuskowski M.A., Selkoe D.J., Ashe K.H. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat. Neurosci. 2005, 8:79-84.
8. Kotilinek L.A., Bacskai B., Westerman M., Kawarabayashi T., Younkin L., Hyman B.T., Younkin S., Ashe K.H. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J. Neurosci. 2002, 22:6331-6335.
9. Lesne S., Koh T.M., Kotilinek L., Kayed R., Glabe C.G., Yang A., Gallagher M., Ashe K.H. A specific amyloid-β protein assembly in the brain impairs memory. Nature 2006, 440:352-357.
10. Stine W.B., Dahlgren K.N., Krafft G.A., LaDu M.J. In vitro characterization of conditions for amyloid-β peptide oligomerization and fibrillogenesis. J. Biol. Chem. 2003, 278:11612-11622.
11. Foguel D., Robinson C.R., Sousa P.C., Silva J.L., Robinson A.S. Hydrostatic pressure rescues native protein from aggregates. Biotechnol. Bioeng. 1999, 552-558.
12. Bharadwaj P.R., Dubey A.K., Masters C.L., Martins R.N., Macreadie I.G. Aβ aggregation and possible implications in Alzheimer's disease pathogenesis. J. Cell. Mol. Med. 2009, 13:412-421.
13. Barghorn S., Nimmrich V., Striebinger A., Krantz C., Keller P., Janson B., Bahr M., Schmidt M., Bitner R.S., Harlan J., Barlow E., Ebert U., Hillen H. Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease. J. Neurochem. 2005, 95:834-847.
14. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M. Diffusible nonfibrillar ligands derived from Ab1-Ab42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA 1998, 95:6448-6453.
15. Lambert M.P., Viola K.L., Chromy B.A., Chang L., Morgan T.E., Yu J., Venton D.L., Krafft G.A., Finch C.E., Klein W.L. Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. J. Neurochem. 2001, 79:595-605.
16. Brining S.K. Predicting the in vitro toxicity of synthetic beta-amyloid (1-40). Neurobiol. Aging. 1997, 18:581-589.
17. Bharadwaj P., Waddington L., Varghese J., Macreadie I.G. A new method to measure cellular toxicity of non-fibrillar and fibrillar Alzheimer's Aβ using yeast. J. Alzheimer's Dis. 2008, 13:1-4.
18. Caine J., Volitakis I., Cherny R., Varghese J., Macreadie I. Aβ produced as a fusion to maltose binding protein can be readily purified and stably associates with copper and zinc. Protein Pept. Lett. 2007, 14:83-86.
19. Ida N., Hartmann T., Pantel J., Schroder J., Zerfass R., Forstl H., Sandbrink R., Masters C.L., Beyreuther K. Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J. Biol. Chem. 1996, 271:22908-22914.
20. Vagin A., Teplyakov A. MOLREP: an automated program for molecular replacement. J. Appl. Crystallogr. 1997, 30:1022-1025.
21. Quiocho F.A., Spurlino J.C., Rodseth L.E. Extensive features of tight oligosaccharide binding revealed in high-resolution structures of the maltodextrin transport/chemosensory receptor. Structure 1997, 5:997-1015.
22. Wilkins D.K., Grimshaw S.B., Receveur V., Dobson C.M., Jones J.A., Smith L.J. Hydrodynamic radii of native and denatured proteins measured by pulse field gradient NMR techniques. Biochemistry 1999, 38:16424-16431.
23. Quillin M.L., Matthews B.W. Accurate calculation of the density of proteins. Acta Crystallogr. D Biol. Crystallogr. 2000, 56:791-794.
24. Ciccotosto G.D., Tew D., Curtain C.C., Smith D., Carrington D., Masters C.L., Bush A.I., Cherny R.A., Cappai R., Barnham K.J. Enhanced toxicity and cellular binding of a modified amyloid beta peptide with a methionine to valine substitution. J. Biol. Chem. 2004, 279:42528-42534.
25. Barnham K.J., Ciccotosto G.D., Tickler A.K., Ali F.E., Smith D.G., Williamson N.A., Lam Y.H., Carrington D., Tew D., Kocak G., Volitakis I., Separovic F., Barrow C.J., Wade J.D., Masters C.L., Cherny R.A., Curtain C.C., Bush A.I., Cappai R. Neurotoxic redox-competent Alzheimer's beta-amyloid is released from lipid membrane by methionine oxidation. J. Biol. Chem. 2003, 278:42959-42965.
26. Yankner B.A., Duffy L.K., Kirschner D.A. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science 1990, 250:279-282.
27. Hung L.W., Ciccotosto G.D., Giannakis E., Tew D.J., Perez K., Masters C.L., Cappai R., Wade J.D., Barnham K.J. Amyloid-beta peptide (Aβ) neurotoxicity is modulated by the rate of peptide aggregation: Aβ dimers and trimers correlate with neurotoxicity. J. Neurosci. 2008, 28:11950-11958.
28. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., Selkoe D.J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002, 416:535-539.
29. Singh S.K., Julliamsa A., Nuydensk R., Ceuterick C., Labeur C., Serneels S., Vennekens K., van Osta P., Geerts H., de Strooper B., Van Broeckhoven C. In vitro studies of Flemish, Dutch, and wild-type β-amyloid provide evidence for two-staged neurotoxicity. Neurobiol. Dis. 2002, 11:330-340.
30. Kobe B., Center R.J., Kemp B.E., Poumbourios P. Crystal structure of human T cell leukemia virus type 1 gp21 ectodomain crystallized as a maltose-binding protein chimera reveals structural evolution of retroviral transmembrane proteins. Proc. Natl. Acad. Sci. USA 1999, 96:4319-4324.